Find Clinical Trials

201 Results

Protocol Code	Study Title	Active substance/Medical device	Study Phase	Therapeutic Area
AG120-881-C-001	A Phase 1, Multicenter, Randomized, Controlled, Open-label, Perioperative Study of AG-120 and AG-881 in Subjects…	AG-120, AG881	Phase 1	Cancers
AG270-C-001	A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors…	AG-270	Phase 1	Cancers
AG120-C-009	A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in…	AG-120, Ivosidenib	Phase 3	Cancers
AG120-C-002	A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study…	AG-120	Phase 1	Cancers
AG120-C-001	A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study…	AG120	Phase 1	Cancers
AG120-221-C-001	A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction…	AG-120, AG-221	Phase 1	Cancers
CL2-95014-002	A Multicentre, Phase II Randomized Study, Open-label, With 2-arm Parallel Group, Comparing the Pharmacokinetics of…	PEGASPARGASE, S095014	Phase 2	Cancers
CL2-95014-003	A Multicentre, Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients…	PEGASPARGASE, S095014	Phase 2	Cancers
CL1-RTCMP-001	Update in progress Target Involvement and Exploratory Biomarkers Investigations in Healthy Volunteers and in Patients With Type 2…		Phase 1	Cardiovascular Diseases
CL2-95015-001	A Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol…	Calaspargase pegol, S095015	Phase 2-3	Cancers
CL2-62798-010	A Multicentre, Randomized, Double-blind, Placebo-controlled Dose-finding Study of S62798 in Patients with Intermediate-High Risk Acute…	S062798	Phase 2	Cardiovascular Diseases
CL1-65487-003	Phase I / II, Open Label, Dose Escalation Part (Phase I) Followed by Noncomparative Expansion…	S065487	Phase 1-2	Cancers
CL3-95005-007	An open-label, randomised, phase III study comparing trifluridine/tipiracil in combination with bevacizumab to trifluridine/tipiracil monotherapy…	TIPIRACIL, TRIFLURIDINE, S095005	Phase 3	Cancers
CL1-64315-004	Phase I/II, international, multicentre, open-label, non-randomised, non-comparative, study evaluating the safety, tolerability and clinical activity…	S064315	Phase 1-2	Cancers
CL2-95011-001	A phase IIa efficacy and safety trial with intravenous S95011 in primary Sjögren’s Syndrome patients.…	S095011	Phase 2	Immune-Inflammatory Diseases
CL3-05167-005	Efficacy and safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in adult patients with arterial…	ATORVASTATIN, PERINDOPRIL, S005167	Phase 3	Cardiovascular Diseases
CL1-95014-001	A Phase 2 Clinical Study of Pegaspargase in Patients With Newly Diagnosed, Untreated Acute Lymphoblastic…	PEGASPARGASE, S095014	Phase 2	Cancers
CL1-64315-003	A Phase I/II, open label, non-randomized study to evaluate safety, tolerability, pharmacokinetics and clinical activity…	S064315	Phase 1-2	Cancers
CL3-13001-002	Clinical Investigation to Determine the Accuracy and Benefit of Cardioskin™ in Patients With Known Atrial…	Cardioskin™	Phase 3	Cardiovascular Diseases
331602	Post Marketing Surveillance Study for ONIVYDE® in South Korea	Liposomal Irinotecan, S095013	Phase 4	Cancers
331501	Phase II Randomized Study of BAX2398 in Combination With 5-Fluorouracil and Calcium Levofolinate in Japanese…	Liposomal Irinotecan, S095013	Phase 2	Cancers
CL1-65487-002	Study of a New Intravenous Drug, Called S065487, in Patients With Acute Myeloid Leukemia, Non…	S065487	Phase 1	Cancers
CL1-64315-002	An International Phase Ib Multicentre Study to Characterize the Safety and Tolerability of Intravenously Administered…	S064315	Phase 1	Cancers
CL3-95008-002	Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less…	BUMETANIDE, S095008	Phase 3	Neuropsychiatric Diseases
CL3-95008-001	Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7…	BUMETANIDE, S095008	Phase 3	Neuropsychiatric Diseases